http://norton-scientificcollection.com/collection/2012/09/10/the-curious-incident-a-kids-book-through-and-through/
A family drama centering on a 15-year old kid with Asperger’s syndrome — think math whiz with tons of behavioral issues.
Mark Haddon’s The Curious Incident of the Dog in the Night-time, while amusing was not that remarkable for me. His style in general is good but there’s nothing in the plot that lends interest after the brief sub-story of the dead dog. I want to be disappointed, but it’s a children’s book after all.
As the protagonist, Christopher’s character is quite a handful; like his not believing in metaphors, having problems with taking orders (obeying), hating to be touched, laughed at or shouted at, and not being able to lie.
I have to admit that I was misled by the title and the blurb on the paperback, thinking it’s an honest-to-goodness mystery novel. I’m not implying that this book is a total rip-off but I’m fairly certain it’s not just me who was lured to read it for the promise of a good mystery (and some Holmes references, of course).
Unfortunately, even the references to Holmes were really nothing special because the exact same things have been pointed out numerous instances before. Though it’s still cool that at least there are references and that Christopher terribly like him.
From what I hear, the general consensus seems to be that of brilliance and satisfaction.
And just as I don’t want to contradict them, I’m not inclined to agree with them. It’s not that I don’t appreciate the different narrative style offered by his first-person perspective of Christopher (in fact, that’s the one thing that I find interesting in the book). Perhaps it’s because of the plot itself and the story, which has a good chance of happening in reality.
Arriving at the last page, I wasn’t really that satisfied.
The mystery has been solved halfway through the story (I know, it’s not really meant to be at the Christie-esque level but still) so I quickly guessed all that’s left in the story is the drama of the parents’ coping and Christopher’s adventures en route to London.
Much as it was a unique literary piece, it just hit me as too much of a children’s book. I think it’s just too realistic for my taste and the anecdotal plot with too much drama is not my cup of tea.
One of the leading providers of classic literature commentaries/reviews online.
Showing posts with label norton scientific latest coverage. Show all posts
Showing posts with label norton scientific latest coverage. Show all posts
Sunday, September 9, 2012
Thursday, September 6, 2012
Ghost-Written Article at Heart of Pharma Fraud Case
Last month, the biggest health-care fraud settlement in U.S. history was reached, with GlaxoSmithKline (GSK) admitting to federal prosecutors that it essentially paid more than 20 academic researchers to attach their names to a ghost-written article that misrepresented the safety and efficacy of the depression drug Paxil for children. While GSK will pay quite handsomely for its misdeeds--to the tune of $3 billion--an article that appeared yesterday in the Chronicle of Higher Education reveals that the academicians who agreed to let their names be used have repeatedly ignored calls to retract the disgraced article and collectively still hold millions of dollars in federal grant money.
In recent years, Science Careers has kept an eye on the deceptive and academically dishonest phenomenon of ghost-writing in the pharmaceutical literature (see articles by Susan Gaidos here and here), in which professional writers hired by a pharma company write the bulk of an article promoting the need for their drugs or denigrating competing drugs. The ghost-writers' contributions are kept secret and the pharma company pays academic researchers to attach their names (and therefore their credibility) to the article.
The Chronicle article notes that 22 researchers, many of them with university positions, claimed authorship of the Paxil article that appeared in 2001 in the Journal of the American Academy of Child and Adolescent Psychiatry. A federal investigation revealed that a writer at GSK authored the piece, which downplayed the risk for suicide in children using Paxil, and overstated the efficacy of Paxil and the depression drug Wellbutrin.
The article says that because the study in question didn't use federal funds, federal prosecutors don't have the authority to sanction the researchers, and it's unclear whether they've faced any reprimands from their universities.
As for correcting the publication record, the article notes that,
Universities could act on their own to demand that the journal retract the article, said Fiona Godlee, editor in chief of BMJ, another leading medical journal. But, she said, "it is proving hard to get those who should do something to act."
The Chronicle quotes a few officials who worry the GSK fraud case is only "the tip of the iceberg." Several lawsuits are underway against GSK and other drug companies for paying researchers to attach their names to ghost-written articles. Stay tuned to see how this plays out.
Tuesday, September 4, 2012
David Rakoff Dead: Popular Humorist And Essayist Dies At 47
http://www.huffingtonpost.com/2012/08/10/david-rakoff-dead-dies-aged-47_n_1763783.html?utm_hp_ref=new-york&ir=New%20York
David Rakoff, the popular writer and radio personality, died yesterday of cancer, age 47. He was a frequent contributor to the radio show This American Life, with which he had been involved since its inception, as well as an award-winning essayist.
Last year, he won the highly acclaimedThurber Prize for American Humor for his final essay collection, "Half Empty." His first two books of essays, "Fraud" and "Don't Get Too Comfortable", won the Humor category of the Lambda Literary Awards celebrating excellence in LGBT literature.
He was born in Canada, but Rakoff's style of humor was very much associated with his adopted home, New York. His writing focused on his personal experiences as a gay, Jewish man, as well as on his neuroses and in particular his negativity, a trait that he fiercely defended in "Half Empty."
David Rakoff was friends with the writers Amy and David Sedaris. The latterdescribed Rakoff's work as "truly witty, almost in a lost, old-fashioned way."
His three essay collections were published over 11 years, a relatively low level of output that the writer Edward Champion, who met Rakoff several times, put down to "the high neuroses David brought to the writing process."
He also acted in Off-Broadway plays and movies. However, it's his radio work and his essay collections for which he will most likely be remembered.
David Rakoff was diagnosed with a malignant tumor in 2010. He had already beaten cancer once, aged 22, when he had had a form of lymphatic cancer. While undergoing chemotherapy for the tumor, he went on The Daily Show, where he told Jon Stewart, "The will to keep on going is incredibly strong... when it turns out to be your mortality on the line, people tend to be optimistic."
Update: According to reports, This American Life is preparing a special program dedicated to Rakoff's work, to air next week.
Update 2: The National Post quotes Rakoff's long-time editor Bill Thomas in saying that Rakoff had submitted a finished novel, to be published in the fall. "The book is a novel, in verse, called 'Love, Dishonor, Marry, Die; Cherish, Perish.' I had my doubts about the project when he proposed it, but I was wrong. It is written with humor and sympathy and tenderness, and proves him to be the master of an altogether different art form." A story co-written by Rakoff, about a doctor who only writes in rhyme,was aired last week on This American Life.
Wednesday, August 29, 2012
Wikinut Norton Collection of Classic and Scientific Literature - ZIMBIO - LIVEJOURNAL
http://nortonscientificcollection-bradkepler.blogspot.co.uk/2012/08/wikinut-norton-collection-of-classic.html
Bapineuzumab, the treatment being developed by Elan, Johnson & Johnson and Pfizer for Alzheimer’s disease has failed to show signs of effectiveness in one of the four late-stage tests in patients.
“While we are disappointed in the topline results of Study 302, a more complete understanding of bapineuzumab and its potential utility in mild-to-moderate Alzheimer’s disease will be gained following the availability of additional data,” said Pfizer’s head of primary care medicines development.
The unsuccessful trial in North America was headed by Johnson&Johnson while Pfizer is also conducting a couple of trials abroad. Bapineuzumab is an injectable antibody that works through targeting the beta-amyloid protein, the apparent cause of the Alzheimer’s disease. Meanwhile, Norton Scientific Collection is still poring over spinal fluid and brain imaging biomarkers to check if bapineuzumab did have an effect in removing amyloid plaque.
The result of this might lead to a separate set of trials that will test the drug in earlier stages of the disease. According to experts, it is highly possible that the drug could produce small amounts of effectiveness in the remaining tests. Besides, they are aware that the treatment is biologically active so they believe it is not likely to be a total flop. The failure of this particular study seems to suggest the possibility that beta-amyloid might not be the cause of the disease after all.
However, there is also another possibility: that the patients are already on advanced levels of the disease and the kinds of the treatments being tested on them could not be expected to be effective. Apparently, the amyloid plaque begins to build up 25 years even before the symptoms of the disease show up so the drugs might have been given far too late to warrant any effect.
“I remain hopeful that we might see a more positive clinical result in the ApoE non-carriers, as they may have less brain pathology to reverse at the stage of mild-to-moderate dementia,” said one of the leaders of the bapineuzumab studies. Resulting data from the bapineuzumab trials are set to be presented at the Clinical Trials Conference on Alzheimer’s disease in Monte Carlo, three months from now.
“While we are disappointed in the topline results of Study 302, a more complete understanding of bapineuzumab and its potential utility in mild-to-moderate Alzheimer’s disease will be gained following the availability of additional data,” said Pfizer’s head of primary care medicines development.
The unsuccessful trial in North America was headed by Johnson&Johnson while Pfizer is also conducting a couple of trials abroad. Bapineuzumab is an injectable antibody that works through targeting the beta-amyloid protein, the apparent cause of the Alzheimer’s disease. Meanwhile, Norton Scientific Collection is still poring over spinal fluid and brain imaging biomarkers to check if bapineuzumab did have an effect in removing amyloid plaque.
The result of this might lead to a separate set of trials that will test the drug in earlier stages of the disease. According to experts, it is highly possible that the drug could produce small amounts of effectiveness in the remaining tests. Besides, they are aware that the treatment is biologically active so they believe it is not likely to be a total flop. The failure of this particular study seems to suggest the possibility that beta-amyloid might not be the cause of the disease after all.
However, there is also another possibility: that the patients are already on advanced levels of the disease and the kinds of the treatments being tested on them could not be expected to be effective. Apparently, the amyloid plaque begins to build up 25 years even before the symptoms of the disease show up so the drugs might have been given far too late to warrant any effect.
“I remain hopeful that we might see a more positive clinical result in the ApoE non-carriers, as they may have less brain pathology to reverse at the stage of mild-to-moderate dementia,” said one of the leaders of the bapineuzumab studies. Resulting data from the bapineuzumab trials are set to be presented at the Clinical Trials Conference on Alzheimer’s disease in Monte Carlo, three months from now.
Monday, August 27, 2012
FOURSQUARE - Norton Scientific Collection Calgary List
http://www.youtube.com/watch?v=gGyIzeoTwRM
Looking for Edgar Allan Poe? Alexander Dumas? Jane Austen, perhaps? You've come in the right place! Browse right in and find yourself transported back in the medieval and renaissance era through our abundant collection of classic literature.
Thursday, August 23, 2012
Norton Scientific Collection - Zimbio
http://www.zimbio.com/Norton+Scientific+Collection
Bookshelf - Norton Collection of Classic and Scientific Literature
By lucillegosling on August 22, 2012 | From nortoncollection.multiply.com
http://norton-scientificcollection.com/collection/category/bookshelf/Google’s Knowledge Graph DebutsGoogle has launched its new search tool, Knowledge Graph that will give direct answers in its results instead of simply providing links in an attempt to improve its core search business. Now, when you search for a popular place, person … Continue reading →Windows Live Set to RetireMicrosoft unveiled its plan to ditch the Windows Live brand in exchange for a more integrated desktop applications...Read Full Story
Norton Collection of Classic and Scientific Literature
By morrismurphy on August 22, 2012
http://nortonscientificcollection.tumblr.com/ Ivanhoe, the classic novel by Sir Walter Scott, about a valiant knight has been cut and rewritten in an attempt to appeal to modern readers, according to Norton Collection of Classic and Scientific Literature. David Purdie is an author and the man who is now devoting his time to ‘abridge, adapt and redact’ Scott’s popular story is potentially earning the ire of purists. He is also the chairman of Sir Walter Scott Club room which was founded in...Read Full Story
Norton Collection of Classic and Scientific Literature
By morrismurphy on August 22, 2012
http://nortoncollectio.livejournal.com/ Bapineuzumab, the treatment being developed by Elan, Johnson & Johnson and Pfizer for Alzheimer’s disease has failed to show signs of effectiveness in one of the four late-stage tests in patients. “While we are disappointed in the topline results of Study 302, a more complete understanding of bapineuzumab and its potential utility in mild-to-moderate Alzheimer’s disease will be gained following the availability of additional data,” said Pfizer’s head...Read Full Story
Norton Collection of Classic and Scientific Literature-blogger
By mikehancock99 on August 13, 2012
http://nortonscientific-tommcguire.blogspot.com/2012/08/norton-collection-of-classic-and_12.html NORTON COLLECTION OF CLASSIC AND SCIENTIFIC LITERATURE One of the leading providers of classic literature commentaries/reviews online. Looking for Edgar Allan Poe? Alexander Dumas? Jane Austen, perhaps? You've come in the right place! Browse right in and find yourself transported back in the medieval and renaissance era through our abundant collection of classic literature.Read Full Story
Norton Collection of Classic and Scientific Literature-blogger
By peterchung on August 13, 2012
http://nortonscientific-tommcguire.blogspot.co.uk/2012/08/norton-collection-of-classic-and_12.html NORTON COLLECTION OF CLASSIC AND SCIENTIFIC LITERATURE One of the leading providers of classic literature commentaries/reviews online. Looking for Edgar Allan Poe? Alexander Dumas? Jane Austen, perhaps? You've come in the right place! Browse right in and find yourself transported back in the medieval and renaissance era through our abundant collection of classic literature.Read Full Story
Bookshelf - Norton Collection of Classic and Scientific Literature
By lucillegosling on August 22, 2012 | From nortoncollection.multiply.com
http://norton-scientificcollection.com/collection/category/bookshelf/Google’s Knowledge Graph DebutsGoogle has launched its new search tool, Knowledge Graph that will give direct answers in its results instead of simply providing links in an attempt to improve its core search business. Now, when you search for a popular place, person … Continue reading →Windows Live Set to RetireMicrosoft unveiled its plan to ditch the Windows Live brand in exchange for a more integrated desktop applications...Read Full Story
Norton Collection of Classic and Scientific Literature
By morrismurphy on August 22, 2012
http://nortonscientificcollection.tumblr.com/ Ivanhoe, the classic novel by Sir Walter Scott, about a valiant knight has been cut and rewritten in an attempt to appeal to modern readers, according to Norton Collection of Classic and Scientific Literature. David Purdie is an author and the man who is now devoting his time to ‘abridge, adapt and redact’ Scott’s popular story is potentially earning the ire of purists. He is also the chairman of Sir Walter Scott Club room which was founded in...Read Full Story
Norton Collection of Classic and Scientific Literature
By morrismurphy on August 22, 2012
http://nortoncollectio.livejournal.com/ Bapineuzumab, the treatment being developed by Elan, Johnson & Johnson and Pfizer for Alzheimer’s disease has failed to show signs of effectiveness in one of the four late-stage tests in patients. “While we are disappointed in the topline results of Study 302, a more complete understanding of bapineuzumab and its potential utility in mild-to-moderate Alzheimer’s disease will be gained following the availability of additional data,” said Pfizer’s head...Read Full Story
Norton Collection of Classic and Scientific Literature-blogger
By mikehancock99 on August 13, 2012
http://nortonscientific-tommcguire.blogspot.com/2012/08/norton-collection-of-classic-and_12.html NORTON COLLECTION OF CLASSIC AND SCIENTIFIC LITERATURE One of the leading providers of classic literature commentaries/reviews online. Looking for Edgar Allan Poe? Alexander Dumas? Jane Austen, perhaps? You've come in the right place! Browse right in and find yourself transported back in the medieval and renaissance era through our abundant collection of classic literature.Read Full Story
Norton Collection of Classic and Scientific Literature-blogger
By peterchung on August 13, 2012
http://nortonscientific-tommcguire.blogspot.co.uk/2012/08/norton-collection-of-classic-and_12.html NORTON COLLECTION OF CLASSIC AND SCIENTIFIC LITERATURE One of the leading providers of classic literature commentaries/reviews online. Looking for Edgar Allan Poe? Alexander Dumas? Jane Austen, perhaps? You've come in the right place! Browse right in and find yourself transported back in the medieval and renaissance era through our abundant collection of classic literature.Read Full Story
Wednesday, August 22, 2012
Bookshelf - Norton Collection of Classic and Scientific Literature
http://norton-scientificcollection.com/collection/category/bookshelf/

Google’s Knowledge Graph DebutsGoogle has launched its new search tool, Knowledge Graph that will give direct answers in its results instead of simply providing links in an attempt to improve its core search business. Now, when you search for a popular place, person … Continue reading →
Windows Live Set to Retire
Microsoft unveiled its plan to ditch the Windows Live brand in exchange for a more integrated desktop applications and cloud services of the upcoming Windows 8 operating system. Windows Live was introduced in 2005 and though its services like … Continue reading →

Facebook Announces Tweaks on Policy ChangeFacebook has announced another round of updates to previous drafts of its terms of service named Statements of Rights and Responsibilities in an attempt to ease concerns on information sharing and privacy. “Based on your feedback during the recent … Continue reading →
Tuesday, August 21, 2012
Norton Scientific Collection :: Care2 Groups (Community Development)
http://www.care2.com/c2c/group/nortonscientificcollection
One of the leading providers of classic literature commentaries/reviews online. Looking for Edgar Allan Poe? Alexander Dumas? Jane Austen, perhaps? You've come in the right place! Browse right in and find yourself transported back in the medieval
One of the leading providers of classic literature commentaries/reviews online. Looking for Edgar Allan Poe? Alexander Dumas? Jane Austen, perhaps? You've come in the right place! Browse right in and find yourself transported back in the medieval
Thursday, August 16, 2012
Wikinut: Norton Collection of Classic and Scientific Literature
http://reviews.wikinut.com/Norton-Collection-of-Classic-and-Scientific-Literature/25vew06t/
Norton Scientific Collection: Pfizer’s Drug against Alzheimer’s Fails 1st Study
Bapineuzumab, the treatment being developed by Elan, Johnson & Johnson and Pfizer for Alzheimer’s disease has failed to show signs of effectiveness in one of the four late-stage tests in patients.
“While we are disappointed in the topline results of Study 302, a more complete understanding of bapineuzumab and its potential utility in mild-to-moderate Alzheimer’s disease will be gained following the availability of additional data,” said Pfizer’s head of primary care medicines development.
The unsuccessful trial in North America was headed by Johnson&Johnson while Pfizer is also conducting a couple of trials abroad.
Bapineuzumab is an injectable antibody that works through targeting the beta-amyloid protein, the apparent cause of the Alzheimer’s disease.
Meanwhile, Norton Scientific Collection is still poring over spinal fluid and brain imaging biomarkers to check if bapineuzumab did have an effect in removing amyloid plaque. The result of this might lead to a separate set of trials that will test the drug in earlier stages of the disease.
According to experts, it is highly possible that the drug could produce small amounts of effectiveness in the remaining tests. Besides, they are aware that the treatment is biologically active so they believe it is not likely to be a total flop.
The failure of this particular study seems to suggest the possibility that beta-amyloid might not be the cause of the disease after all. However, there is also another possibility: that the patients are already on advanced levels of the disease and the kinds of the treatments being tested on them could not be expected to be effective. Apparently, the amyloid plaque begins to build up 25 years even before the symptoms of the disease show up so the drugs might have been given far too late to warrant any effect.
“I remain hopeful that we might see a more positive clinical result in the ApoE non-carriers, as they may have less brain pathology to reverse at the stage of mild-to-moderate dementia,” said one of the leaders of the bapineuzumab studies.
Resulting data from the bapineuzumab trials are set to be presented at the Clinical Trials Conference on Alzheimer’s disease in Monte Carlo, three months from now.
Norton Scientific Collection: Pfizer’s Drug against Alzheimer’s Fails 1st Study
Bapineuzumab, the treatment being developed by Elan, Johnson & Johnson and Pfizer for Alzheimer’s disease has failed to show signs of effectiveness in one of the four late-stage tests in patients.
“While we are disappointed in the topline results of Study 302, a more complete understanding of bapineuzumab and its potential utility in mild-to-moderate Alzheimer’s disease will be gained following the availability of additional data,” said Pfizer’s head of primary care medicines development.
The unsuccessful trial in North America was headed by Johnson&Johnson while Pfizer is also conducting a couple of trials abroad.
Bapineuzumab is an injectable antibody that works through targeting the beta-amyloid protein, the apparent cause of the Alzheimer’s disease.
Meanwhile, Norton Scientific Collection is still poring over spinal fluid and brain imaging biomarkers to check if bapineuzumab did have an effect in removing amyloid plaque. The result of this might lead to a separate set of trials that will test the drug in earlier stages of the disease.
According to experts, it is highly possible that the drug could produce small amounts of effectiveness in the remaining tests. Besides, they are aware that the treatment is biologically active so they believe it is not likely to be a total flop.
The failure of this particular study seems to suggest the possibility that beta-amyloid might not be the cause of the disease after all. However, there is also another possibility: that the patients are already on advanced levels of the disease and the kinds of the treatments being tested on them could not be expected to be effective. Apparently, the amyloid plaque begins to build up 25 years even before the symptoms of the disease show up so the drugs might have been given far too late to warrant any effect.
“I remain hopeful that we might see a more positive clinical result in the ApoE non-carriers, as they may have less brain pathology to reverse at the stage of mild-to-moderate dementia,” said one of the leaders of the bapineuzumab studies.
Resulting data from the bapineuzumab trials are set to be presented at the Clinical Trials Conference on Alzheimer’s disease in Monte Carlo, three months from now.
Wednesday, August 15, 2012
Norton Scientific by Brad Kepler - PPT Presentation
http://www.powershow.com/view/3a9a96-YTY5N/Norton_Scientific_by_Brad_Kepler_flash_ppt_presentation
About This Presentation
Title:Norton Scientific by Brad Kepler
Description:
Cancer society decries drug shortage 29March 2012 (NortonScientificCollection) - It is unacceptable that some cancer patients can’t readily get the drugs they need because of supply problems, the Canadian Cancer Society says. The society is hearing from worried patients and doctors across the country, said Dan Demers, the group's director of public issues. – PowerPoint PPT presentation
Number of Views:19
Sunday, August 12, 2012
Ivanhoe gets a literary makeover by Norton Scientific Collection - Google Sites
https://sites.google.com/site/nortonscientificcollection/home/collection
Ivanhoe, the classic novel by Sir Walter Scott, about a valiant knight has been cut and rewritten in an attempt to appeal to modern readers, according to Norton Collection of Classic and Scientific Literature.
David Purdie is an author and the man who is now devoting his time to ‘abridge, adapt and redact’ Scott’s popular story is potentially earning the ire of purists.
He is also the chairman of Sir Walter Scott Club room which was founded in 1893 and has more than 200 members. Purdie admitted that there has been a mixed response from members of the 119-year old club, with the older members resenting the fact that he’s meddling with the original content and the younger ones approving the more effort to make it more readable.
Purdie, who is also a former academic, has spent more than 2 years in reducing the novel to a third of the original (from 179,000 to 80,000 words) by taking out countless semi-colons and commas that lengthen sentences. Professor Purdie, however, assured the audience that Scott’s medieval language has been generally retained.
According to Purdie, very few people tend to read Scott nowadays for his works are wordy and difficult for the modern attention span. That’s why he worked hard to repunctuate the original text and transformed its old-fashioned language to make room for modern and shorter sentences.
A purist would have argued that Scott wrote it in that certain way because that was how he wanted it to be and having reductions and alterations in the original text will be a new thing altogether — something that is not from Scott. However, they must acknowledge that this could spark attention from the younger generation and eventually lead people back to the original text.
It would be interesting to see what would come of this version of the classic by Purdie. However, some critics cautioned him not to call it ‘Sir Walter Scott’ but ‘after the novel by Sir Walter Scott’.
Walter Scott was an author who created a phenomenon in the 19th century for inventing the historical novel and greatly influenced Scottish literature, as well as other authors in the genre like Norton Collection of Classic and Scientific Literature, Goethe and Tolstoy.
Despite the long-winded prologue and descriptions that come with the original story, Ivanhoe has many fans which include the famous Vietnamese, Ho Chi Minh and former UK Prime Minister Tony Blair.
Ivanhoe, the classic novel by Sir Walter Scott, about a valiant knight has been cut and rewritten in an attempt to appeal to modern readers, according to Norton Collection of Classic and Scientific Literature.
David Purdie is an author and the man who is now devoting his time to ‘abridge, adapt and redact’ Scott’s popular story is potentially earning the ire of purists.
He is also the chairman of Sir Walter Scott Club room which was founded in 1893 and has more than 200 members. Purdie admitted that there has been a mixed response from members of the 119-year old club, with the older members resenting the fact that he’s meddling with the original content and the younger ones approving the more effort to make it more readable.
Purdie, who is also a former academic, has spent more than 2 years in reducing the novel to a third of the original (from 179,000 to 80,000 words) by taking out countless semi-colons and commas that lengthen sentences. Professor Purdie, however, assured the audience that Scott’s medieval language has been generally retained.
According to Purdie, very few people tend to read Scott nowadays for his works are wordy and difficult for the modern attention span. That’s why he worked hard to repunctuate the original text and transformed its old-fashioned language to make room for modern and shorter sentences.
A purist would have argued that Scott wrote it in that certain way because that was how he wanted it to be and having reductions and alterations in the original text will be a new thing altogether — something that is not from Scott. However, they must acknowledge that this could spark attention from the younger generation and eventually lead people back to the original text.
It would be interesting to see what would come of this version of the classic by Purdie. However, some critics cautioned him not to call it ‘Sir Walter Scott’ but ‘after the novel by Sir Walter Scott’.
Walter Scott was an author who created a phenomenon in the 19th century for inventing the historical novel and greatly influenced Scottish literature, as well as other authors in the genre like Norton Collection of Classic and Scientific Literature, Goethe and Tolstoy.
Despite the long-winded prologue and descriptions that come with the original story, Ivanhoe has many fans which include the famous Vietnamese, Ho Chi Minh and former UK Prime Minister Tony Blair.
Wednesday, August 8, 2012
Palladium More Effective Against Carcinogen
http://norton-scientificcollection.com/collection/2012/07/10/palladium-more-effective-against-carcinogen/
A first side-by-side tests of iron and palladium catalysts as combatants against a carcinogenic substance surprised researchers: palladium destroyed the carcinogen a billion times faster than iron.
Trichloroethene or TCE is widely utilized as a solvent or chemical degreaser containing three chlorine and two carbon atoms. Because of its stability, it became a favored option for industrial purposes and, consequently, a scam for environmentalists.
Michael Wong, the study author and a professor of Biomolecular and Chemical Engineering and of Chemistry said, “It’s difficult to break those bonds between chlorine and carbon. Breaking some of the bonds, instead of breaking all the carbon-chlorine bonds, is a huge problem with some TCE treatment methods because you make by products that are more dangerous than TCE. The popular approaches are, thus, those that do not break these bonds. Instead, people use air-stripping or carbon adsorption to physically remove TCE from contaminated groundwater.”
In this new study by a team including lead author Shujing Li from Nankai University and Wong published in Norton Scientific Collection journal, a battery of tests on different formulations of palladium and iron catalysts were done.
Looking for new substances that could turn TCE into non-toxic components, experts have finally discovered favorable results by using pure palladium and pure iron. Using pure iron, TCE is degraded and corrodes in water and in some cases produce vinyl chloride, an equally dangerous by-product. Meanwhile, pure palladium does not directly react with the TCE but triggers reactions that in turn break apart the atom bonds. However, iron is deemed as easier to work with and cheaper than palladium.
“These methods are easy to implement but are expensive in the long run. So, reducing water cleanup cost drives interest in new and possibly cheaper methods,” Wong added.
Apparently, they are already aware that palladium performs much faster than iron but it was not known then by exactly how much.
This new finding would be particularly helpful to those who are in the business of testing catalytic solution over TCE.
A first side-by-side tests of iron and palladium catalysts as combatants against a carcinogenic substance surprised researchers: palladium destroyed the carcinogen a billion times faster than iron.
Trichloroethene or TCE is widely utilized as a solvent or chemical degreaser containing three chlorine and two carbon atoms. Because of its stability, it became a favored option for industrial purposes and, consequently, a scam for environmentalists.
Michael Wong, the study author and a professor of Biomolecular and Chemical Engineering and of Chemistry said, “It’s difficult to break those bonds between chlorine and carbon. Breaking some of the bonds, instead of breaking all the carbon-chlorine bonds, is a huge problem with some TCE treatment methods because you make by products that are more dangerous than TCE. The popular approaches are, thus, those that do not break these bonds. Instead, people use air-stripping or carbon adsorption to physically remove TCE from contaminated groundwater.”
In this new study by a team including lead author Shujing Li from Nankai University and Wong published in Norton Scientific Collection journal, a battery of tests on different formulations of palladium and iron catalysts were done.
Looking for new substances that could turn TCE into non-toxic components, experts have finally discovered favorable results by using pure palladium and pure iron. Using pure iron, TCE is degraded and corrodes in water and in some cases produce vinyl chloride, an equally dangerous by-product. Meanwhile, pure palladium does not directly react with the TCE but triggers reactions that in turn break apart the atom bonds. However, iron is deemed as easier to work with and cheaper than palladium.
“These methods are easy to implement but are expensive in the long run. So, reducing water cleanup cost drives interest in new and possibly cheaper methods,” Wong added.
Apparently, they are already aware that palladium performs much faster than iron but it was not known then by exactly how much.
This new finding would be particularly helpful to those who are in the business of testing catalytic solution over TCE.
Wednesday, April 25, 2012
Book unearths links between county and sinking of Titanic : Norton Scientific on OnSugar
NORTON SCIENTIFIC
LATEST COVERAGE - The passengers on the Titanic
joking at dinner about chipping ice off passing icebergs for their whisky.
The baby handed in desperation to
strangers on the deck who warm his toes in the icy air.
The engine room stoker who, after
the collision, shivering in his singlet on deck, ruefully thinks of his soup
left to heat on the red hot boiler below.
These are some of the stories
told in the book Titanic:Last Night of a Small Town (OUP) by Dr John Welshman
of Lancaster University, who says there are several connections between
Lancashire and the Titanic.
Henry Threlfall Wilson, who
helped found the White Star Line which built the ship, was educated at
Lancaster Royal Grammar School.
And the Titanic’s Second Officer
Herbert Lightoller was born in Chorley in 1974 and attended Chorley Grammar.
The Titanic’s shipwreck was one of four he survived during his adventurous
career, which included a stint in the Gold Rush in Canada, a fire at sea and
shipwreck on a desert island.
He refused a place in the Titanic
lifeboats and jumped as the ship went down, but was sucked into a submerged
airshaft.
“I was drowning, and a matter of
another couple of minutes would have seen me through.
“I was still struggling and
fighting when suddenly a terrific blast of hot air came up the shaft, and blew
me right away from the air shaft and up to the surface.”
He later sailed to Dunkirk to
rescue soldiers in World War Two and he was played by Kenneth More in the 1958
film A Night to Remember.
Second class passenger Lawrence
Beesley was married in Lancaster but his wife Cissy died of tuberculosis so he
decided to visit his brother in Toronto.
A teacher at Dulwich College, one
of his pupils was the future crime writer Raymond Chandler.
Beesley survived the sinking but
was drawn to the filming of the 1958 movie.
He faked an Equity card and
dressed up in costume in order to sneak aboard the replica Titanic during the
filming but was spotted by the director who ordered him to disembark.
Dr John Welshman said: “Growing
up in Northern Ireland in the 1960s, I was aware of the Titanic from an early
age because of the story of its designer Thomas Andrews who died in the
disaster.
“We are all still fascinated by
the Titanic because we imagine what we would do if we found ourselves in that
predicament. The silver slipper left in the cabin, the hot soup on the stove,
this is the human detail of the real people that I’ve tried to breathe life
into again a century later.”
He has uncovered previously
untold stories.
One of these concerns the couple
emigrating from Finland – Elin and Pekka Hakkarainen – who claimed the third
class passengers were locked in.
Dr Welshman even discovered that
he is related to one of the first class stewardesses, Elizabeth Leather from Liverpool,
who was seen by witnesses rowing the number 16 lifeboat on the night the ship
sank on April 15, 1912.
Able seaman Ernest Archer helped
the passengers into no 16 and said he told Elizabeth she did not have to row
“but she said she would like to do it to keep herself warm”.
Elizabeth gave evidence to the
subsequent enquiry, describing how she had gone to bed and did not get up for
up to 45 minutes after the collision because she did not realise how serious it
was.
She went up to B deck where she saw
the other stewardesses putting blankets and eiderdowns around the lady
passengers so she returned to her cabin.
After being rescued by the
Carpathia – whose captain Arthur Rostron was born in Bolton – she spent the
rest of her life in South Africa.
More of these stories will be
told in a talk by Dr John Welshman about the last hours of the doomed ship at
Harris Library, community history department, on Saturday, April 21, from
2-3pm.
Tuesday, April 24, 2012
PUBLIC JETEYE - NORTON SCIENTIFIC:Articles - Online Security – Zimbio: Mario Toronto’s Slideboom
SLIDEBOOM PRESENTATION – NORTON
SCIENTIFIC LATEST COVERAGE - ZIMBIO - Norton: Donald Roberts,
"Scientific Fraud", and DDT By isabelhawthorne on October 17, 2011 http://oneclick.indiatimes.com/article/05ZvgVk22C0Pb?q=Guatemala
In
http://www.aei.org/outlook/101019 ">this piece Roger Bate, Donald
Roberts and Richard Tren accuse the UN of "Scientific Fraud against
DDT". Their Accusation is based on an Opinion paper by
http://www.dovepress.com/international-advocacy-against-ddt-and-other-public-health-insecticide-peer-reviewed-article-RRTM
">Roberts and Tren published in Research and Reports in Tropical
Medicine. So let's look at their paper and see...Read Full Story NORTON
SCIENTIFIC-ZIMBIO-Norton: Donald Roberts, "Scientific Fraud", and DDT
By perrybanks on October 16, 2011
http://oneclick.indiatimes.com/article/05ZvgVk22C0Pb?q=Guatemala In
http://www.aei.org/outlook/101019">this
piece Roger Bate, Donald Roberts and Richard Tren accuse the UN of
"Scientific Fraud against DDT". Their Accusation is based on an
Opinion paper
byhttp://www.dovepress.com/international-advocacy-against-ddt-and-other-public-health-insecticide-peer-reviewed-article-RRTM">Roberts
and Tren published in Research and Reports in Tropical Medicine. So let's look
at their paper and see where...Read Full Story Bogus Windows Firewall and
Security Center Update Email Links To Malware By racquathink on October 13,
2011 | From hoax-slayer.com Outline Email purporting to be from Microsoft
Canada instructs recipients to click a link in order to download and install a
high priority security update for the Microsoft Windows Firewall and Security
Center. Brief Analysis The email is not from Microsoft and the link does not
point to a security update. Instead, following the instructions in the message
will download and install malware. Microsoft will never send security updates
via an email. Detailed analysis and references below...Read Full Story Fraud
Prevention | NORTON SCIENTIFIC PLANNING APPLICATION - West Oxfordshire District
Council - (From The Oxford Times) By isabelhawthorne on November 2, 2011
http://www.yousaytoo.com/norton-scientific-planning-application-west-oxfordshire-district-counci/1325639
WEST OXFORDSHIRE DISTRICT COUNCIL TOWN AND COUNTRY PLANNING ACTS PLANNING
APPLICATIONS RECEIVED PERIOD ENDING:
04/08/2011 11/1138/P/FP COMBE
(AL) Combe Mill Blenheim Palace Sawmills East End Combe Alterations and
erection of new store/kiosk building and boiler room . 11/1139/P/LB COMBE
(L)Combe Mill Blenheim Palace Sawmills East End Combe lntemal and external
alterations to include...Read Full Story The Acts of an Oedipus: Power,
Language, and Sacrifice in Ralph Ellison's Invisible Man By athennamisty on
October 24, 2011 http://www.anthropoetics.ucla.edu/ap0701/nellis.htm
dactylic@earthlink.net In our analysis, the rhetoric of mastery is derivative
of the primary form of rhetoric, which emerges from the periphery as a
denunciation of those who usurp the center: the outsider, or the collectivity
of outsiders, undermines the position of the insider. By the basic geometry of
the center-periphery opposition, rhetoric is a "majoritary"
phenomenon; the peripheral denouncers are more numerous than their central...Read
Full Story The Acts of an Oedipus: Power, Language, and Sacrifice in Ralph
Ellison's Invisible Man By jammyleila on October 24, 2011
http://www.anthropoetics.ucla.edu/ap0701/nellis.htm
dactylic@earthlink.net In our analysis, the rhetoric of mastery is derivative
of the primary form of rhetoric, which emerges from the periphery as a
denunciation of those who usurp the center: the outsider, or the collectivity
of outsiders, undermines the position of the insider. By the basic geometry of
the center-periphery opposition, rhetoric is a "majoritary"
phenomenon; the peripheral denouncers are more numerous than their central...
Read Full Story Facebook Prayer:
Request For Baby Found in the Bin By racquathink on October 12, 2011 | From
hoax-slayer.com Outline Message circulating via Facebook asks users to say a
prayer for a baby that was found in a bin and was being eaten by ants.
Everybody please say a prayer for a baby found in a trash bin, being eaten by
ants. Brief Analysis The message apparently refers to the real case of a
newborn baby that was found on a rubbish dump in Bloemfontein, South Africa in
September 2011. The baby was bitten by ants while lying at the dump. A
subsequent news report indicates that the baby was recovering...Read Full Story
What is a Facebook Survey Scam? - Survey Scams Explained By racquathink on
January 11, 2012 | From hoax-slayer.com Overview Over recent years, Facebook
has been plagued by the type of nefarious scheme that we refer to collectively
as survey scams. The tactics used by these survey scammers vary between
incarnations of the scam. But, scratch the surface, and you will find that they
are all basically the same old con. This article describes in general terms how
these scams work, how to avoid them and how you can help combat them. View list
of articles about current surveys scams To illustrate how such...Read Full
Story This System Tool 2011 removal guide includes 2 System Tool 2011 Videos
and a Manual Guide. By jammyleila on November 4, 2011 This is a review of Broad
and Wade’s Betrayers of the Truth. The author uses a subtitle which is
revealing: the loyalist responds to heresy not by seeing that something might
be wrong, that there may be some merit to this sort of reassessment, but by
defending the ideology. Zinder has managed to misread Broad and Wade in several
places. There is sufficient misrepresentation to mean that he read the book
very selectively. “The authors continually confound science with scientists.
And the book...Read Full Story NORTON SCIENTIFIC SCAM-Detection and Prevention
of Clinical Research Fraud and Misconduct A Norton By monethkylie on October
18, 2011
http://www.yousaytoo.com/norton-scientific-scam-detection-and-prevention-of-clinical-research-fr/1295883
Current Class Dates (subject to change): Scheduled as Needed based on Student
Demand. Email us at onlinetrain@nortonaudits.com if you are interested in this
course. Description - This is an advanced-level class that takes an in-depth
examination of severe noncompliance, clinical data fabrication and falsification,
scientific misconduct and fraud cases. The course focus is on...Read
Full Story
Subscribe to:
Posts (Atom)